International Publisher of Science, Technology and Medicine

 
 
Share this
 
 
 
 

Journal of Primary &
Acquired Immunodeficiency Research

Editorial Board: Jeffrey A. Frelinger, PhD
 University of Arizona, USA  view all
ISSN: 2324-853X
Frequency: Biannual
Formerly: Journal of Immunodeficiency & Disorders
 

Journal of Primary & Acquired Immunodeficiency Research is a peer-reviewed scholarly journal that aims to publish the most complete and reliable source of information on the discoveries and current developments in the form of original articles, full/mini reviews, case reports, commentaries, letter to editor, rapid/short communications, etc. in all areas pertaining to Immunodeficiency, making them available online freely without any restrictions or subscription to researchers worldwide.

Journal of Primary & Acquired Immunodeficiency Research publishes results of research on Primary Immunodeficiecny, Acquired Immunodeficiency, Diseases/Infections/Disorders associated with Immunodeficiency and their Treatments

 The Journal uses Editorial Manager System to maintain quality review process. Editorial Manager is an online manuscript submission, review and tracking system. Review process is performed by the editorial board members of Journal of Primary & Acquired Immunodeficiency Research or outside experts; the validation by at least two independent reviewers followed by the editor’s approval is required for the acceptance of any citable manuscript for publication in the Journal. Authors may submit manuscripts and track its progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor in the Editorial Manager System. Editors can manage the entire submission/review/revision/publication process.

Submit manuscript at http://www.editorialmanager.com/scitechnol/ or send as an e-mail attachment to the Editorial Office at editor.jpair@scitechnol.com or editor.jpair@scitechnol.net

Journal of Primary & Acquired Immunodeficiency Research is organizing and supporting 3rd International Conference on Clinical & Cellular Immunology during September 29- October 01, 2014 to be held at Baltimore, USA and 2nd International Conference on HIV/AIDS, STDs & STIs during October 27- October 29, 2014 to be held at Las Vegas, USA

 

 

 
Current Issue
Editors & Editorial Board Members  
J Immunodefic Disor 2013, 2:1   
  PDF   
Mast Cells as Reservoirs for HIV Latency   Editorial
Silvia Bulfone-Paus
J Immunodefic Disor 2013, 2:1    doi: 10.4172/2324-853X.1000e108
 Preview

Mast Cells as Reservoirs for HIV Latency

More than a decade ago, Bannert and colleagues first reported that human mast cell (MC) progenitors are susceptible to infection with HIV-1. This finding was confirmed and extended by other groups in the following years providing in vivo evidence that tissue MCs, developing from infected human MC progenitors, remain productively infected in infected people. Moreover, evidence was shown that Toll-like receptor (TLR) 2, TLR4, or TLR9 stimulation of latently infected mast cells induced re-initiation of HIV-1 replication.

|  Full Text |   PDF   
Gene Therapy in Primary Immunodeficiencies   Review Article
Inês Rosinha, Laura Costa, Mara Pinto, Natália Barbosa and Patrícia Rosinha
J Immunodefic Disor 2013, 2:1    doi: 10.4172/2324-853X.1000103
 Preview

Gene Therapy in Primary Immunodeficiencies

Primary immunodeficiencies (PIDs) result from inherited mutations in genes involved in the production, function or survival of specific elements of the immune system (T, B, NK lymphocytes, neutrophils, antigen-presenting cells). Knowing that these elements derive from pluripotent hematopoietic stem cells, it has been tried to use allogeneic hematopoietic stem cell transplantation (HSCT) as an alternative for patients with a PID, which has proven to be an effective  therapeutic approach leading to immune restoration.

|  Full Text |   PDF   
Non-Antibacterial Implications of Tetracyclines in the Management of Periodontitis: An Update   Research Article
Bangalore Varadhan Karthikeyan, Devireddy Venkata Tejaswi and Munivenkatappa Lakshmaiah Venkatesh Prabhuji
J Immunodefic Disor 2013, 2:1    doi: 10.4172/2324-853X.1000104
 Preview

Non-Antibacterial Implications of Tetracyclines in the Management of Periodontitis: An Update

Recent research has shown that the majority of the soft and hard tissue destruction in periodontitis occurs due to activated host immuneinflammatory defence mechanisms in response to bacterial plaque. The importance of the host inflammatory response in periodontal pathogenesis presents opportunity for exploring new treatment strategies for periodontitis by means of host modulation. One of such treatment strategy is the use of drugs like Chemically Modified Tetracyclines, which are derivatives of tetracycline group of antibiotics, but lack antimicrobial action and have potent host modulating properties. The main advantage of Chemically Modified Tetracyclines over conventional tetracyclines is that they do not produce the side effects such as gastro-intestinal toxicity and antibiotic resistance.

 

|  Full Text |   PDF   
Effect of Different Hydatid Cyst Molecules on Hela and Vero Cell Lines Growth In vitro   Research Article
Nasir Aref, Hedayatollah Shirzad, Morteza Yousefi and Hossein Yousofi Darani
J Immunodefic Disor 2013, 2:1    doi: 10.4172/2324-853X.1000105
 Preview

Mast Cells as Reservoirs for HIV Latency

 

Hydatid cyst is the larval stage of the tapeworm, Echinococcus granulosus, a parasite responsible for hydatid disease or hydatidosis in human and livestock. This disease considered as one of the most important cosmopolitan zoonotic infection with different mammalian hosts being involved in the life cycle. It has been shown that in a large retrospective study of patients with cancer, the prevalence of hydatid cyst was significantly lower than in normal subjects. Antitumor activity of some other parasites have also been demonstrated.

|  Full Text |   PDF